Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 10:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Beta-Amyloid Clear all
Terminated Phase 1 Interventional Accepts healthy volunteers

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

NCT00870519
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
I-123-MNI-168, 123-I MNI-168
Drug
Lead sponsor
Institute for Neurodegenerative Disorders
Other
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 2, 2019 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Acute Plasma Abeta Responses to Stress

NCT05521919
View directory record Official record
Conditions
Stress Reaction, Stress Physiology
Interventions
Sympathetic Nervous System Activation, No-stress
Behavioral
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 65 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Tazarotene Cream 0.05% to TAZORAC® (Tazarotene) Cream 0.05% and Both to a Placebo Control in the Treatment of Plaque Psoriasis

NCT02886702
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

RCT: Enzyme Blend Toothpaste on Dental Biofilm Plaque Accumulation

NCT07079683
View directory record Official record
Conditions
Dental Biofilm Accumulation
Interventions
Toothpaste Product
Other
Lead sponsor
Novozymes A/S
Industry
Eligibility
18 Years to 65 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 7, 2025 · Synced Sep 26, 2026, 10:06 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

NCT03721172
View directory record Official record
Conditions
Psoriasis
Interventions
Apremilast, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
43
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Rogers, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 1 Interventional

Magnetic Resonance Imaging of Narrowed Arteries

NCT00029575
View directory record Official record
Conditions
Arteriosclerosis
Interventions
Surgi-Vision Guidewire Coil
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis

NCT02173301
View directory record Official record
Conditions
Psoriasis
Interventions
XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Hot Springs, Arkansas + 25 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2022 · Synced Sep 26, 2026, 10:06 PM EDT
Terminated Phase 2 Interventional

A Non-Randomized Study of the NightHawk Peripheral Plaque Excision System During Plaque Excision of Peripheral Arterial Disease

NCT00516308
View directory record Official record
Conditions
Peripheral Vascular Diseases
Interventions
NightHawk
Device
Lead sponsor
FoxHollow Technologies
Industry
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 17, 2008 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Livionex on Reducing Plaque Accumulation and Improving Oral Health in Children

NCT04368533
View directory record Official record
Conditions
Plaque, Dental, Caries, Dental, Oral Hygiene
Interventions
Livionex Dental Gel, A standard children's toothpaste containing 1500 ppm fluoride
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
9 Months to 12 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

NCT03832738
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis, Skin Diseases
Interventions
JTE-451 Tablets, Placebo Tablets
Drug
Lead sponsor
Akros Pharma Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
6
States / cities
Santa Monica, California • Temecula, California • Indianapolis, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2021 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect of a Novel Sweetener on the pH of Dental Plaque.

NCT00739778
View directory record Official record
Conditions
Dental Caries
Interventions
food - novel sweetener, food vehicle blank, food - sweetener, positive control, food - sweetener, negative control
Other
Lead sponsor
Cargill
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Sep 26, 2026, 10:06 PM EDT
Completed No phase listed Observational

A Proposed Study of Atherosclerotic Plaques in Leg Arteries

NCT01803126
View directory record Official record
Conditions
Vascular Disease, Diabetes
Interventions
Not listed
Lead sponsor
Southwest Regional Wound Care Center
Other
Eligibility
Not listed
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Jun 28, 2018 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens

NCT01406938
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
AIN457 150mg, AIN457 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
967 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Fresno, California • Pasadena, California • Sacramento, California + 28 more
Source: ClinicalTrials.gov public record
Updated May 18, 2015 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis

NCT04664153
View directory record Official record
Conditions
Atopic Dermatitis, Plaque Psoriasis
Interventions
PF-07038124 ointment, Vehicle ointment
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
15
States / cities
Fountain Valley, California • Cape Coral, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)

NCT01597245
View directory record Official record
Conditions
Psoriasis
Interventions
80 mg ixekizumab Dosing Regimen, 50 mg etanercept, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
41
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Sep 26, 2026, 10:06 PM EDT
Withdrawn Phase 2 Interventional

Apremilast for Chronic Plaque Psoriasis (CPP) Patients Who Have Failed One Course of Biologic Therapy

NCT01200264
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
apremilast
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 14, 2014 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of IDP-122 in the Treatment of Participants With Plaque Psoriasis

NCT02515097
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
IDP-122 Lotion, IDP-122 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
15
States / cities
Santa Ana, California • Boynton Beach, Florida • Clearwater, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2020 · Synced Sep 26, 2026, 10:06 PM EDT
Completed No phase listed Observational

Evaluation of the Effectiveness of Secukinumab in Patients With Moderate to Severe Plaque Psoriasis

NCT05344482
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Secukinumab
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Predictor of Advanced Sub-Clinical Atherosclerosis (PASA) Study

NCT00258999
View directory record Official record
Conditions
Atherosclerosis
Interventions
Skin Cholesterol Testing
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
30 Years to 80 Years
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 4, 2015 · Synced Sep 26, 2026, 10:06 PM EDT
Active, not recruiting Not applicable Interventional

Randall's Plaque Study: Pathogenesis and Relationship to Nephrolithiasis

NCT00169806
View directory record Official record
Conditions
Nephrocalcinosis, Renal Calculi, Hypercalciuria, Hyperparathyroidism, Cystinuria
Interventions
videotape for mapping of renal anatomy and papillary biopsy
Other
Lead sponsor
Indiana Kidney Stone Institute
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2025
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 26, 2026, 10:06 PM EDT
Terminated Phase 4 Interventional Results available

CT COMPARE: CT Coronary Angiography to Measure Plaque Reduction

NCT02740699
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Rosuvastatin, Atorvastatin, Cardiac Computed Tomography (CT), Cardiac Magnetic Resonance Image (MRI)
Drug · Radiation
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
40 Years to 75 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 8, 2024 · Synced Sep 26, 2026, 10:06 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Plaque and Tangle Imaging in Aging and Dementia

NCT00355498
View directory record Official record
Conditions
Memory Disorders, Alzheimer's Disease
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
30 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 26, 2026, 10:06 PM EDT
Completed Phase 2 Interventional Results available

BI 655066 Dose Ranging in Psoriasis, Active Comparator Ustekinumab

NCT02054481
View directory record Official record
Conditions
Psoriasis
Interventions
BI 655066, Ustekinumab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
12
States / cities
Los Angeles, California • Port Orange, Florida • Arlington Hts, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Sep 26, 2026, 10:06 PM EDT